LOS ANGELES, Oct. 10 /PRNewswire-FirstCall/ -- Signalife has received additional sales orders in excess of one half million dollars ($551,500 to be exact), during CEO Lowell Harmison's most recent cross-country sales initiative. These purchase orders are currently resulting in revenues to the company such that the company anticipates achieving break-even status by the end of January, 2008, or at the very latest the end of 2008 first quarter.
Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are
"forward- looking" statements. Forward-looking statements involve known and
unknown risks, which may cause Signalife's actual results in the future to
differ materially from expected results. Factors which could cause or
contribute to such differences include, but are not limited to, failure to
complete the development and introduction of heart monitoring and other
biomedical devices incorporating Signalife's technology, failure to obtain
federal or state regulatory approvals governing heart monitoring and other
biomedical devices incorporating Signalife's technology, inability to
obtain physician, patient or insurance acceptance of for heart monitoring
and other biomedical incorporating Signalife's technology, and the
unavailability of financing to complete management's plans and objectives,
including the development of he
|SOURCE Signalife, Inc.|
Copyright©2007 PR Newswire.
All rights reserved